Table 8.
ICER ($) of different Interferons-Beta in comparison to placebo therapy in MS patients according to different utility measurement methods
| Therapy | Literature-based | VAS | EQ-5D | HUI 3 |
|---|---|---|---|---|
|
Interferon beta-1a |
18712 |
19954 |
17398 |
20045 |
|
(Intramuscular) | ||||
|
(Avonex) | ||||
|
Interferon beta-1a |
11832 |
11850 |
10433 |
11437 |
|
(Subcutaneous) | ||||
|
(Rebif) | ||||
|
Interferon beta-1b |
15768 |
16864 |
15030 |
16314 |
|
(Betaferon) | ||||
|
Interferon beta-1a |
847 |
904 |
788 |
908 |
|
(Intramuscular) | ||||
|
(CBPs) | ||||
|
Interferon beta-1a |
6964 |
6975 |
6140 |
6731 |
|
(Subcutaneous) | ||||
|
(CBPs) | ||||
|
Interferon beta-1b |
11913 | 12740 | 11355 | 12325 |
| (CBPs and BS) |
$ US dollars, ICER incremental cost effectiveness ratio, VAS visual analogue scale, EQ-5D EuroQol, HUI3: Health Utilities Index 3, CBPs Copied biopharmaceuticals including IM IFNβ-1a (Cinnovex, Actovex), SC IFNβ-1a (Recigen, Actorif ) and SC IFNβ-1b (Ziferon, Actoferon), BS biosimilar including SC IFNβ-1b (Extavia).